JP2020517599A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517599A5
JP2020517599A5 JP2019555959A JP2019555959A JP2020517599A5 JP 2020517599 A5 JP2020517599 A5 JP 2020517599A5 JP 2019555959 A JP2019555959 A JP 2019555959A JP 2019555959 A JP2019555959 A JP 2019555959A JP 2020517599 A5 JP2020517599 A5 JP 2020517599A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
formula
unit
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019555959A
Other languages
English (en)
Japanese (ja)
Other versions
JP7425606B2 (ja
JP2020517599A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030018 external-priority patent/WO2018201087A1/en
Publication of JP2020517599A publication Critical patent/JP2020517599A/ja
Publication of JP2020517599A5 publication Critical patent/JP2020517599A5/ja
Priority to JP2023113358A priority Critical patent/JP2023119064A/ja
Application granted granted Critical
Publication of JP7425606B2 publication Critical patent/JP7425606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019555959A 2017-04-27 2018-04-27 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート Active JP7425606B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023113358A JP2023119064A (ja) 2017-04-27 2023-07-10 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762490733P 2017-04-27 2017-04-27
US62/490,733 2017-04-27
US201762573987P 2017-10-18 2017-10-18
US62/573,987 2017-10-18
PCT/US2018/030018 WO2018201087A1 (en) 2017-04-27 2018-04-27 Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023113358A Division JP2023119064A (ja) 2017-04-27 2023-07-10 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート

Publications (3)

Publication Number Publication Date
JP2020517599A JP2020517599A (ja) 2020-06-18
JP2020517599A5 true JP2020517599A5 (cg-RX-API-DMAC7.html) 2021-06-17
JP7425606B2 JP7425606B2 (ja) 2024-01-31

Family

ID=62165714

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555959A Active JP7425606B2 (ja) 2017-04-27 2018-04-27 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP2023113358A Pending JP2023119064A (ja) 2017-04-27 2023-07-10 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023113358A Pending JP2023119064A (ja) 2017-04-27 2023-07-10 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート

Country Status (14)

Country Link
US (2) US11931414B2 (cg-RX-API-DMAC7.html)
EP (1) EP3615081A1 (cg-RX-API-DMAC7.html)
JP (2) JP7425606B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190141181A (cg-RX-API-DMAC7.html)
CN (1) CN110799217A (cg-RX-API-DMAC7.html)
AU (2) AU2018258687C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019022445A2 (cg-RX-API-DMAC7.html)
CA (1) CA3060206A1 (cg-RX-API-DMAC7.html)
IL (1) IL269794A (cg-RX-API-DMAC7.html)
MA (1) MA51189A (cg-RX-API-DMAC7.html)
MX (2) MX2019012194A (cg-RX-API-DMAC7.html)
SG (1) SG11201909563VA (cg-RX-API-DMAC7.html)
TW (1) TW201904613A (cg-RX-API-DMAC7.html)
WO (1) WO2018201087A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
CN110339181A (zh) * 2019-07-02 2019-10-18 中国药科大学 一种基于点击反应的pH响应型纳米制剂及其制法和应用
CN118406099A (zh) * 2020-04-02 2024-07-30 中国人民解放军第二军医大学 一种nampt蛋白降解靶向嵌合体及其制备方法和应用
AU2021251875A1 (en) * 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途
CN116092586B (zh) * 2023-03-10 2025-11-04 西北工业大学 一种基于生物电子等排体搜索平台的数据处理方法
WO2025162305A1 (zh) * 2024-02-01 2025-08-07 浙江养生堂天然药物研究所有限公司 含季铵盐的抗体偶联药物及其医药用途
CN119219604B (zh) * 2024-09-25 2025-11-18 大连理工大学 一种吡啶季铵盐类fk866前药、其制备方法及应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU4076500A (en) 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003097602A1 (en) * 2002-05-17 2003-11-27 Leo Pharma A/S Cyanoguanidine produgs
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
WO2009086835A1 (en) 2008-01-11 2009-07-16 Topotarget A/S Novel cyanoguanidines
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
WO2009140418A2 (en) 2008-05-14 2009-11-19 Five Prime Therapeutics, Inc. Compositions and methods for treating arthritis and/or diseases involving cartilage degeneration
MX2010014310A (es) 2008-06-24 2011-02-15 Topotarget As Derivados de acido escuarico como inhibidores de la nicotinamida.
CN102186822A (zh) 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
CA2764694A1 (en) 2009-06-09 2010-12-16 Topotarget A/S Pyridinyl derivatives asinhibitors of enzyme nicotinamide phosphoribosyltransferase
EP2453883A1 (en) 2009-07-17 2012-05-23 Topo Target A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
CN106986856A (zh) 2010-09-03 2017-07-28 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
AR082885A1 (es) 2010-09-03 2013-01-16 Genentech Inc Compuestos y composiciones para la inhibicion de nampt
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
US20120122924A1 (en) 2010-11-15 2012-05-17 Abbott Laboratories Nampt inhibitors
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
JP5978293B2 (ja) 2011-05-04 2016-08-24 フォーマ ティーエム, エルエルシー. Namptを阻害するための新規な化合物および組成物
JP5872027B2 (ja) 2011-05-09 2016-03-01 フォーマ ティーエム, エルエルシー. ニコチンアミドホスホリボシルトランスフェラーゼ(nampt)を阻害するためのピペリジン誘導体および組成物
EP2739144A4 (en) 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
EP2776393B1 (en) 2011-11-11 2017-12-20 Abbvie Inc. Nampt inhibitors
WO2013082150A1 (en) 2011-11-30 2013-06-06 The Curators Of The University Of Missouri Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt)
CN105017420B (zh) 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
EP2852585A1 (en) 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
AR091022A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
MX340090B (es) 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
ITTO20130356A1 (it) 2013-05-03 2014-11-04 Uni Degli Studi Del Piemonte Orientale Ame Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi
WO2015054060A1 (en) 2013-10-09 2015-04-16 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
PT3057585T (pt) * 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
CN106458934B (zh) 2014-04-18 2019-08-16 米伦纽姆医药公司 喹喔啉化合物及其用途
TW201625641A (zh) 2014-05-22 2016-07-16 健臻公司 Nampt抑制劑及方法
EP3172205A1 (en) 2014-07-23 2017-05-31 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
CN104557863B (zh) 2014-12-18 2017-03-15 中国科学院广州生物医药与健康研究院 一种新型烟酰胺磷酸核糖转移酶抑制剂及其合成方法与应用
EP3247705B1 (en) 2015-01-20 2019-11-20 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Similar Documents

Publication Publication Date Title
JP2019524759A5 (cg-RX-API-DMAC7.html)
JP2023082171A5 (cg-RX-API-DMAC7.html)
US7442682B2 (en) Transepithelial delivery of peptides with incretin hormone activities
KR101685734B1 (ko) 지방산 나이아신 접합체 및 그의 용도
CA2199664C (en) Novel prodrugs for the therapy of tumors and inflammatory disorders
JP2019501131A5 (cg-RX-API-DMAC7.html)
JP2020122023A5 (cg-RX-API-DMAC7.html)
HRP20250345T1 (hr) Konjugati antitijelo - lijek derivata cikličnih dinukleotida
TW200813028A (en) Improved prodrugs of CC-1065 analogs
JP2023119064A (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP6704900B2 (ja) ポリオキサゾリン抗体薬物複合体
JP5548365B2 (ja) 核酸系代謝拮抗剤の高分子誘導体
CN108578710A (zh) 用经不可切割接头连接的细胞结合剂美登木素生物碱偶联物
CN105377304B (zh) 鹅膏毒肽衍生物
JP6721512B2 (ja) がん及び炎症性疾患の治療のための結合体及びプロドラッグ
JP2019511497A5 (cg-RX-API-DMAC7.html)
CA3117666A1 (en) Biomarkers of metap2 inhibitors and applications thereof
IL293605A (en) Hydroxyl polyamidoamine dendrimers modified with trihexylated n-acetylgalactosamine and methods of using them
AU2006218187A1 (en) Transport of nano- and macromolecular structures into cytoplasm and nucleus of cells
WO2020014541A2 (en) Compounds, compositions, methods, and uses for treating cancer and immunological disorders
JP2026509773A (ja) アルブミン結合性部分を含む薬物化合物
EP3484523A1 (en) Conjugation method for carrier-linked prodrugs
JP2019520342A5 (cg-RX-API-DMAC7.html)
US20110152200A1 (en) Methods and compositions for inhibition of bcl6 repression
AR129066A1 (es) Conjugados de ligando-fármaco con propiedades farmacocinéticas y de liberación de fármaco mejoradas